814 related articles for article (PubMed ID: 17329466)
21. A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: comparison of antipsychotics for metabolic problems (CAMP).
Stroup TS; McEvoy JP; Ring KD; Hamer RH; LaVange LM; Swartz MS; Rosenheck RA; Perkins DO; Nussbaum AM; Lieberman JA;
Am J Psychiatry; 2011 Sep; 168(9):947-56. PubMed ID: 21768610
[TBL] [Abstract][Full Text] [Related]
22. Choice of randomization to clozapine versus other second generation antipsychotics in the CATIE schizophrenia trial.
Hermes E; Rosenheck R
J Psychopharmacol; 2012 Sep; 26(9):1194-200. PubMed ID: 22516668
[TBL] [Abstract][Full Text] [Related]
23. Noninferiority of perphenazine vs. three second-generation antipsychotics in chronic schizophrenia.
Rosenheck R; Lin H
J Nerv Ment Dis; 2014 Jan; 202(1):18-24. PubMed ID: 24375207
[TBL] [Abstract][Full Text] [Related]
24. Effectiveness of antipsychotic treatments for schizophrenia: interim 6-month analysis from a prospective observational study (IC-SOHO) comparing olanzapine, quetiapine, risperidone, and haloperidol.
Dossenbach M; Erol A; el Mahfoud Kessaci M; Shaheen MO; Sunbol MM; Boland J; Hodge A; O'Halloran RA; Bitter I;
J Clin Psychiatry; 2004 Mar; 65(3):312-21. PubMed ID: 15096069
[TBL] [Abstract][Full Text] [Related]
25. Impact of antipsychotic treatment on nonfasting triglycerides in the CATIE Schizophrenia Trial phase 1.
Meyer JM; Davis VG; McEvoy JP; Goff DC; Nasrallah HA; Davis SM; Daumit GL; Hsiao J; Swartz MS; Stroup TS; Lieberman JA
Schizophr Res; 2008 Aug; 103(1-3):104-9. PubMed ID: 18534821
[TBL] [Abstract][Full Text] [Related]
26. Response and relapse in patients with schizophrenia treated with olanzapine, risperidone, quetiapine, or haloperidol: 12-month follow-up of the Intercontinental Schizophrenia Outpatient Health Outcomes (IC-SOHO) study.
Dossenbach M; Arango-Dávila C; Silva Ibarra H; Landa E; Aguilar J; Caro O; Leadbetter J; Assunção S
J Clin Psychiatry; 2005 Aug; 66(8):1021-30. PubMed ID: 16086618
[TBL] [Abstract][Full Text] [Related]
27. Time to discontinuation of atypical versus typical antipsychotics in the naturalistic treatment of schizophrenia.
Ascher-Svanum H; Zhu B; Faries D; Landbloom R; Swartz M; Swanson J
BMC Psychiatry; 2006 Feb; 6():8. PubMed ID: 16504026
[TBL] [Abstract][Full Text] [Related]
28. Results of phase 3 of the CATIE schizophrenia trial.
Stroup TS; Lieberman JA; McEvoy JP; Davis SM; Swartz MS; Keefe RS; Miller AL; Rosenheck RA; Hsiao JK;
Schizophr Res; 2009 Jan; 107(1):1-12. PubMed ID: 19027269
[TBL] [Abstract][Full Text] [Related]
29. Effectiveness of antipsychotic drugs against hostility in patients with schizophrenia in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) study.
Volavka J; Czobor P; Citrome L; Van Dorn RA
CNS Spectr; 2014 Oct; 19(5):374-81. PubMed ID: 24284234
[TBL] [Abstract][Full Text] [Related]
30. Comparison of quetiapine and risperidone in the treatment of schizophrenia: A randomized, double-blind, flexible-dose, 8-week study.
Zhong KX; Sweitzer DE; Hamer RM; Lieberman JA
J Clin Psychiatry; 2006 Jul; 67(7):1093-103. PubMed ID: 16889453
[TBL] [Abstract][Full Text] [Related]
31. Ziprasidone versus olanzapine, risperidone or quetiapine in patients with chronic schizophrenia: a 12-week open-label, multicentre clinical trial.
Lublin H; Haug HJ; Koponen H; Sigmundsson T; Kolb SA
World J Biol Psychiatry; 2009; 10(4 Pt 3):710-8. PubMed ID: 18803070
[TBL] [Abstract][Full Text] [Related]
32. Cognitive effects of atypical antipsychotic medications in patients with Alzheimer's disease: outcomes from CATIE-AD.
Vigen CL; Mack WJ; Keefe RS; Sano M; Sultzer DL; Stroup TS; Dagerman KS; Hsiao JK; Lebowitz BD; Lyketsos CG; Tariot PN; Zheng L; Schneider LS
Am J Psychiatry; 2011 Aug; 168(8):831-9. PubMed ID: 21572163
[TBL] [Abstract][Full Text] [Related]
33. Comparative efficacy between clozapine and other atypical antipsychotics on depressive symptoms in patients with schizophrenia: analysis of the CATIE phase 2E data.
Nakajima S; Takeuchi H; Fervaha G; Plitman E; Chung JK; Caravaggio F; Iwata Y; Mihashi Y; Gerretsen P; Remington G; Mulsant B; Graff-Guerrero A
Schizophr Res; 2015 Feb; 161(2-3):429-33. PubMed ID: 25556080
[TBL] [Abstract][Full Text] [Related]
34. Sexual dysfunction associated with second-generation antipsychotics in outpatients with schizophrenia or schizoaffective disorder: an empirical evaluation of olanzapine, risperidone, and quetiapine.
Byerly MJ; Nakonezny PA; Bettcher BM; Carmody T; Fisher R; Rush AJ
Schizophr Res; 2006 Sep; 86(1-3):244-50. PubMed ID: 16730951
[TBL] [Abstract][Full Text] [Related]
35. Clinical implications of the CATIE schizophrenia trials: day-to-day management lessons for Australasian psychiatrists.
Bick P; Knoesen N; Castle D
Australas Psychiatry; 2007 Dec; 15(6):465-9. PubMed ID: 17999256
[TBL] [Abstract][Full Text] [Related]
36. Effectiveness of second-generation antipsychotics: a naturalistic, randomized comparison of olanzapine, quetiapine, risperidone, and ziprasidone.
Johnsen E; Kroken RA; Wentzel-Larsen T; Jørgensen HA
BMC Psychiatry; 2010 Mar; 10():26. PubMed ID: 20334680
[TBL] [Abstract][Full Text] [Related]
37. Discontinuation of treatment of schizophrenic patients is driven by poor symptom response: a pooled post-hoc analysis of four atypical antipsychotic drugs.
Liu-Seifert H; Adams DH; Kinon BJ
BMC Med; 2005 Dec; 3():21. PubMed ID: 16375765
[TBL] [Abstract][Full Text] [Related]
38. One-year, randomized, open trial comparing olanzapine, quetiapine, risperidone and ziprasidone effectiveness in antipsychotic-naive patients with a first-episode psychosis.
San L; Arranz B; Perez V; Safont G; Corripio I; Ramirez N; Dueñas R; Alvarez E
Psychiatry Res; 2012 Dec; 200(2-3):693-701. PubMed ID: 22954905
[TBL] [Abstract][Full Text] [Related]
39. Frequency of sexual dysfunction and other reproductive side-effects in patients with schizophrenia treated with risperidone, olanzapine, quetiapine, or haloperidol: the results of the EIRE study.
Bobes J; Garc A-Portilla MP; Rejas J; Hern Ndez G; Garcia-Garcia M; Rico-Villademoros F; Porras A
J Sex Marital Ther; 2003; 29(2):125-47. PubMed ID: 12623765
[TBL] [Abstract][Full Text] [Related]
40. Risperidone, quetiapine, and fluphenazine in the treatment of patients with therapy-refractory schizophrenia.
Conley RR; Kelly DL; Nelson MW; Richardson CM; Feldman S; Benham R; Steiner P; Yu Y; Khan I; McMullen R; Gale E; Mackowick M; Love RC
Clin Neuropharmacol; 2005; 28(4):163-8. PubMed ID: 16062094
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
